Modeling genetic platelet disorders with human pluripotent stem cells: mega-progress but wanting more on our plate(let). Issue 5 (September 2021)

• Record Type: Journal Article
• Authors: Nations, Catriana C.; Pavani, Giulia; French, Deborah L.; Gadue, Paul
• Is Part Of: Current opinion in hematology. Volume 28:Issue 5(2021)
• Publication Date: 2021-09
• Subjects: disease modeling -- induced pluripotent stem cell -- megakaryocytes -- platelet defects; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1097/MOH.0000000000000671
• Languages: English
• ISSNs: 1065-6251

Abstract

Abstract : Purpose of review: Megakaryocytes are rare hematopoietic cells that play an instrumental role in hemostasis, and other important biological processes such as immunity and wound healing. With the advent of cell reprogramming technologies and advances in differentiation protocols, it is now possible to obtain megakaryocytes from any pluripotent stem cell (PSC) via hematopoietic induction. Here, we review recent advances in PSC-derived megakaryocyte (iMK) technology, focusing on platform validation, disease modeling and current limitations. Recent findings: A comprehensive study confirmed that iMK can recapitulate many transcriptional and functional aspects of megakaryocyte and platelet biology, including variables associated with complex genetic traits such as sex and race. These findings were corroborated by several pathological models in which iMKs revealed molecular mechanisms behind inherited platelet disorders and assessed the efficacy of novel pharmacological interventions. However, current differentiation protocols generate primarily embryonic iMK, limiting the clinical and translational potential of this system. Summary: iMK are strong candidates to model pathologic mutations involved in platelet defects and develop innovative therapeutic strategies. Future efforts on generating definitive hematopoietic progenitors would improve current platelet generation protocols and expand our capacity to model neonatal and adult megakaryocyte disorders.